Asian Journal of Pharmaceutical Technology & Innovation
ISSN: 2347-8810

Review Article

Received on: 01-10-2014
Accepted on: 10-10-2014
Published on: 15-10-2014

Corresponding Author:

*** Pramod Singh Khatri**

Head of Department &
Programme Coordinator,
Clinical Research,
Amity Medical School,
Amity University ,
Haryana, India.

QR Code AJPTI

*Email Id-
pramodsinghkhatri@gmail.com

Pharmacogenomics & Pharmacogenetics (PGx) - A Connexion to Personalized Cancer Therapy

Pramod Singh Khatri[1], Ankita Kaushal[2]

ABSTRACT

In the recent years, headways in Pharmacogenetics and pharmacogenomics (PGx) have gradually revealed the genetic premise of inter individual contrasts in drug reactions. A tangible parcel of these developments has been made in the field of anticancer treatment. PGx mostly center to illuminate the genomic elements of medication mien and its impact.

As tumor chemotherapy is generally non-particular and has limited remedial index, there is an incredible probability for pharmacogenomics to enhance treatment by either diminishing the various types of toxicity or escalating the efficacy. As of late, the US FDA has redesigned approx. 30 anticancer biomarkers to incorporate PGx data which incorporates the unpredictability of hereditary information (e.g. Cancer mutation, chromosomal translocation and germ line mutations).

Key-words: Pharmacogenetics, pharmacogenomics, cancer, drug development, hereditary

Cite this article as:
Pramod Singh Khatri, Ankita Kaushal, Pharmacogenomics & Pharmacogenetics (PGx) - A Connexion to Personalized Cancer Therapy, Asian Journal of Pharmaceutical Technology & Innovation, 02 (08); 2014.

1 HOD, Clinical Research, Amity Medical School, Amity University, Haryana, India.
2 MSc.Clinical Research, Amity Medical School, Amity University, Haryana, India.

INTRODUCTION:

The objective of PGx is to customize therapy focused around individual's genotype. Till date the accomplishment of PGx has spread over all fields of medicine[1-4] .The US FDA has suggested PGx prescription for more than 120 medications with connections to more than 50 genes. These medications are usually recommended in the treatment of cancer malignancies, cardiovascular and psychiatric disease[5-6]. Genetic data has been utilized as the distinguishing proof of malady risk (example BRCA1 mutation test to assess breast cancer risk), decision of treatment executors (CYP2D6 in breast cancer treatment) and the significant medication dosing (CYP2C9 and VKORC1 for warfarin medicating, TPMT for 6-mercaptopurine & azathioprine). Oncologists and hematologists are struggling to individualize tumor treatment in an exertion to expand efficacy and minimize lethality in cancer patients (Figure.1). In anticancer PGxs, genotypic data can encompass, yet is not restricted to SNP, haplotypes, microsatellites, insertion and CNV, aneuploidy and loss of heterozygosity in the tumor[7-10].



Figure -1 *Medications - One Size Does Not Fit Everyone*

Protagonist of genetics in drug retort:

It is critical to figure out if the hereditary variation is liable to have an effect on the phenotype, before directing a PGx study. The most regularly utilized approach within genetics to screen for the vicinity of a heritable trait is Heritability Analysis[11-13]. Its essential objective is to decide the amount of the variation in phenotype can be credited to genetic difference. Heritability measures can go from 0 to 1. A critical heritable constituent for a given phenotype gives a solid establishment to follow up genetic examination (Figure.2).

Notwithstanding, a heritability investigation of lethal medications (anticancer agents) is impractical in unaffected relatives. Rather, a methodology utilizing cell lines from substantial pedigrees has been utilized for a few cytotoxic agents, including bleomycin, cisplatin, docetaxel, 5-Fu and daunorubicin[14-18].



Figure -2 the importance of Genetic testing

Genetic markers for cancer detection:

Cancer is a hereditary malady started by gene alteration, for example, oncogenes and tumor suppressor genes that direct cell multiplication, survival, and other homeostatic function[19-20]. A few proto oncogenes get changed over into oncogenes with as meager as a point transformation on a chromosome, accordingly modifying the measure of its product i.e. protein .these translocations serve as very particular tumor markers for remarkable clinical analysis.

Once the genetic commitment is affirmed, the following step is to distinguish the causative genetic markers for the phenotypes of investment, which can be as particular as gene expression. There are 2 methodologies used to assess how hereditary variation subsidizes human variations in medication reaction and lethality: candidate gene and GWAS approach[21-23].

Candidate Gene Approach:

The candidate gene methodology to directing hereditary association studies concentrates on relationship between hereditary variety inside pre specified genes of interest and phenotypes. Candidate genes are frequently chosen for study focused around from the earlier knowledge of the gene's effect on the trait. The reason behind concentrating on allelic variation in particular, biologically applicable allele regions of the genome is that few mutations will straightforwardly affect the function of the gene being referred to, and lead to the phenotype or malady state being examined[24].

The speculation is that hereditary variation in gene that assume a critical part in the pharmacokinetics or pharmacodynamics of a medication would likely influence the drug's viability and toxicity quality. A positive finding through a candidate gene methodology is not difficult to decipher and can yield clinically pertinent data. In any case, a negative result can be translated in numerous diverse ways. Frequently, the sample size is so little, it is not possible to recognize an impact, there may be an absence of inclusion of the causal hereditary polymorphism, or there may be a genuine nonattendance of an impact.

In oncology, the candidate gene methodology has concentrated on gene encoding substances included in the digestion system or transport of anticancer executors, and additionally medication targets and downstream events prompting apoptosis[25-28]. These studies are normally led utilizing clinically important samples (e.g., blood, liver, or intestinal tissues), which speak to either drug. Obviously, the germ line DNA sequence continues as before paying little mind to the tissue of inception. In this way, the sample collection site is frequently focused around practical issues, and also the phenotypes of investment (e.g., tissue-particular gene expression). PGx investigation can either concentrate on known SNPs (i.e., genotyping) or the identification of new SNPs (i.e. sequencing).

Genome Wide Approach:

GWAS methodologies in PGx allude to the worldwide investigation of hereditary variation inside the human genome for their consequences for medication treatment. The speculation is that any hereditary variation in the human genome can contribute to genetic variation in drug effect[29]. In this manner, these studies are not predispositioned to current knowledge of gene expression and can possibly distinguish numerous hereditary variations that led to complex clinical traits. Latest advances in genomic engineering, for example, microarray genotyping stages (which recognize SNPs and CNVs), microarray-based comparative genomic hybridization (array CGH; which distinguishes CNV), and transcriptional level gene expression platform (which measure mRNA level gene expression), alongside the development of software to achieve the analysis of these large information sets, have permitted scientists to perform GWAS study in the middle of genotypes and phenotypes. GWAS is an investigation of hereditary variation over the human genome, intended to distinguish hereditary relationship with noticeable traits, for example, pulse or weight, with/ without a malady or a condition[30]. Similarly with all PGx clinical studies, an unmistakably characterized phenotype of interest is important. Phenotypes assessed in GWAS can be either qualitative/ categorical components (reaction or no reaction, alive or dead) or quantitative/constant measures (cancer volume, negligible leftover disease). Investigating genome scale hereditary information obliges huge computational capacity and for the most part has a high risk of false disclosure of clinical information.

Application of PGx to clinical Drug Development:

A standout amongst the most assuring areas in which PGx investigation can be connected is cancer drug development and early-stage clinical trials. Case in point, particular genotyping can be executed in stratifying the trial populace (genostratification) to attain better treatment accomplishment in clinical trials. By using a hereditarily predefined populace, the application of PGx to clinical studies may support in arriving at "verification of idea" in a shorter time furthermore take into consideration a diminishment in sample size and trial span[31-33]. Distinguishing proof of genetic biomarkers with indicative and prognostic power may lead to accelerate drug development, as well as to oversee post approval risk

(Figure.3). With the advancements in PGx innovations (e.g., genotyping, profiling, proteomics), the importance of candidate gene markers can be utilized for microarrays, proteomics and immunohistochemistry) and in vitro assays[34-37]. The clinical prominence of inherited variations can be further characterized through judiciously outlined prospective clinical trials.

S.No.	Genetic markers /Tumor markers	cancer types	Tissue analyzed	utilization
1	ALK gene rearrangements	NSCLC and anaplastic large cell lymphoma	Tumor	Determine treatment and prognosis
2	Beta-2-microglobulin (B2M)	Multiple myeloma, CLL	Blood, CSF	Determine prognosis and follow response to treatment
3	BCR-ABL fusion gene	Chronic myeloid leukemia	Bone marrow	Confirm diagnosis and monitor disease status
4	BRAF mutation V600E	Cutaneous melanoma and colorectal cancer	Tumor	Predict response to targeted therapies
5	CA15-3/CA27.29	Breast cancer	Blood	Assess whether treatment is working or disease has recurred
6	CA19-9	Pancreatic cancer, and gastric cancer	Blood	Assess whether treatment is working
7	CA-125	Ovarian cancer	Blood	Diagnosis, evaluation of recurrence
8	Calcitonin	Medullary thyroid cancer	Blood	Diagnosis, and assess recurrence
9	Carcino -+ embryonic antigen (CEA)	Colorectal cancer and breast cancer	Blood	Check whether colorectal cancer has spread
10	CD20	Non-Hodgkin lymphoma	Blood	Determine whether treatment with a targeted therapy is appropriate
11	Chromosomes 3, 7, 17, and 9p21	Bladder cancer	Urine	Help in monitoring for tumor recurrence
12	Cytokeratin fragments 21-1	Lung cancer	Blood	Help in monitoring for recurrence
13	EGFR mutation analysis	Non-small cell lung cancer	Tumor	Help determine treatment and prognosis
14	ER and PR receptor	Breast cancer	Tumor	Determine whether treatment with hormonal therapy is appropriate
15	Fibrin/fibrinogen	Bladder cancer	Urine	Monitor progression and response to treatment



Figure -3 the development of a PGx medicine

Closing remarks:

Given the slender remedial catalogues and marked heterogeneity in patient reactions, a finer understanding of the hereditary bases for inter individual contrasts in medication impact can possibly altogether improve the adequacy of chemotherapeutic agents. Also, such data may take into account normal choice of chemotherapy agents and improvement of dosing regimens for individual tumor patients. Surely, consideration of pharmacogenomics clinical data and DNA collection may get to be crucial amid right from early phases of drug development process. Substantial, prospectively planned clinical trials will be important to evaluate the effect and cost effectiveness of genotyping methodologies. Likewise, the application of cancer pharmacogenomics has the prospective for "individualized cancer treatment" regarding the ideal medication combination and dose measurements that maximally profit individual patients.

Acknowledgement:

I wish to thank the student for her critical discussion.

Conflicts of Interest Statement:

The Authors declare no conflicts of interest.

References:

1. Roses AD (June 2000). "Pharmacogenetics and the practice of medicine". Nature 405 (6788): 857–65. doi:10.1038/35015728.
2. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. NatMed. 2006; 12:1294–1300.
3. Griffiths, AJ.; Miller, JH.; Suzuki, DT., et al. An Introduction to Genetic Analysis. W.H. Freemanand Co.; New York: 1996.
4. Oroszi G, Goldman D. Alcoholism: genes and mechanisms. Pharmacogenomics. 2004;5:1037–1048.
5. Schnoll R, Johnson T, Lerman C. Genetics and smoking behavior. Curr Psychiatry Rep. 2007; 9:349–357.
6. Faraday N, Yanek L, Mathias R, et al Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007; 115:2490–2496.
7. Cloos J, Nieuwenhuis E, Boomsma D, et al. Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst. 1999; 91:1125–1130.

8. Dolan ME, Newbold KG, Nagasubramanian R, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004; 64:4353–4356.
9. Watters JW, Kraja A, Meucci MA, et al. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A. 2004; 101:11809–11814
10. Duan S, Bleibel W, Huang R, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 2007; 67:5425–5433.
11. Bosch T, Meijerman I, Beijnen J, Schellens J. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006; 45:253–285.
12. Carter SL, Negrini M, Baffa R, Gillium DR, Rosenberg AL, Schwartz GF, et al. Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res 1994; 54 : 6270-4
13. Zhu M, Zhao S. Candidate Gene Identification Approach: Progress and Challenges. Int J Biol Sci 2007; 3(7):420-427.
14. Bosch T, Meijerman I, Beijnen J, Schellens J. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006; 45:253–285.
15. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther. 2005; 107:155–176.
16. Manolio TA; Guttmacher, Alan E.; Manolio, Teri A. (July 2010). "Genomewide association studies and assessment of the risk of disease". *N. Engl. J. Med.* 363 (2): 166–76. doi:10.1056/NEJMra0905980.
17. Pearson TA, Manolio TA (March 2008). "How to interpret a genome-wide association study". *JAMA* 299 (11): 1335–44. doi:10.1001/jama.299.11.1335.PMID 18349094.
18. "Genome-Wide Association Studies". National Human Genome Research Institute.
19. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J (April 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration". *Science* 308 (5720):385–9
20. Johnson AD, O'Donnell CJ (2009). "An Open Access Database of Genome-wide Association Results". *BMC Med. Genet.* 10:6. doi:10.1186/1471-2350-10-6.
21. Ikram MK, Sim X, Xueling S, *et al.* (October 2010). "Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo". In McCarthy, Mark I. *PLoS Genet.* 6 (10): e1001184. doi:10.1371/journal.pgen.1001184.
22. Rothenberg M. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol. 1998; 25(5 suppl 11):39–46.
23. de Jong F, Scott-Horton T, Kroetz D, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007; 81:42–49.
24. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003;13:741–757.
25. Zhou Q, Sparreboom A, Tan E, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol. 2005; 59:415–424
26. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995; 333:1171–1175.
27. Iyer L, King C, Whitington P, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998; 101:847–854.
28. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687–1717.
29. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005; 23:9312–9318.
30. Goetz MP, Suman VJ, Ingle JN, et al. A 2-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006; 12(7 pt 1):2080–2087.
31. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97:30–39.
32. Massarweh S, Osborne C, Creighton C, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008; 68:826–833.
33. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004). "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6". *J Pharmacol Exp Ther* 310 (3): 1062–75.doi:10.1124/jpet.104.065607.
34. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (December 2000). "Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription". *Cell* 103 (6): 843–52.doi:10.1016/S0092-8674(00)00188-4.
35. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (February 2008). "Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function". *Cancer Res.* 68 (3): 826–33. doi:10.1158/0008-5472.CAN-07-2707.
36. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS (December 2008). "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen". *Nature* 456 (7222): 663–6. doi:10.1038/nature07483. PMC 2920208.
37. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R (March 2003). "Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer". *J. Natl. Cancer Inst.* 95 (5): 353–61. doi:10.1093/jnci/95.5.353.